On November 12, 2025, the highly anticipated 93rd China International Pharmaceutical Raw Materials/Intermediates/Packaging/Equipment Fair (API China) kicked off at the Chongqing International Expo Center. As the "barometer" and "vane" of China's pharmaceutical industry, this year's API China takes serving the innovation of the entire pharmaceutical chain as its core mission, gathers high-quality resources from the entire industry chain, and collaborates with more than 1000 enterprises covering various fields such as pharmaceutical raw materials, intermediates, pharmaceutical excipients, pharmaceutical packaging, and pharmaceutical equipment. It gathers with more than 5000 pharmaceutical production enterprises and nearly 30000 industry colleagues in Shancheng, building a super platform that integrates product display, technical exchange, and business cooperation. Under the dual drive of global supply chain restructuring and industrial upgrading, such aggregation effects are not only an opportunity for enterprises to seek vitality, but also an important lever for China's pharmaceutical industry to shape new development advantages.
The precise focus on segmented exhibition areas and efficient aggregation of full chain resources have become prominent highlights of this year's API China. In the special exhibition area of biopharmaceutical supply chain, the full chain resources of raw material supply, production and manufacturing, cold chain logistics, compliance services, etc. are concentrated and showcased, building a key bridge between research and development achievements and market landing, providing valuable opportunities for exhibitors to face more than 100 innovative pharmaceutical companies and CRO/CDMO leading enterprises, and helping to share the new blue ocean of trillion level industry.
The "Pharmaceutical R&D Supply Chain Exhibition Area" launched at the exhibition has attracted much attention to the pain points and difficulties in the field of pharmaceutical research and development. This exhibition area relies on the profound accumulation of API China's full industry chain platform, with exhibits covering the complete chain of "target discovery → CMC → clinical → registration → commercial production". It comprehensively connects key links such as drug project approval, research and development quality control, and production circulation, providing practical solutions to solve industry difficulties such as "pipeline screening difficulties, hospital admission difficulties, and medical insurance payment difficulties", and promoting the transformation of the industry from technology output to ecological win-win.
At present, China's pharmaceutical industry is in a critical period of overlapping three waves of "carbon neutrality, continuous manufacturing, and biopharmaceuticals", and high-end pharmaceutical equipment is entering a golden window driven by "domestic substitution+overseas dual wheels". During the exhibition, the pharmaceutical equipment sector focused on the core theme of "Green, Intelligent, and Symbiosis", bringing together 12 specialized sectors including raw material drug production machinery and equipment, formulation production machinery and equipment, biopharmaceutical production equipment, packaging equipment, environmental protection equipment, clean and purification equipment, and automation. We are committed to creating a comprehensive value platform that connects the upstream and downstream of the pharmaceutical equipment industry chain, showcasing high-quality products, facilitating trade exchanges, and sharing technology.
In the early winter of 2025, Chongqing International Expo Center witnessed an important gathering of China's pharmaceutical industry. The 93rd API China is not only an exhibition, but also an important stage for China's pharmaceutical industry to achieve self breakthrough. Here, every handshake is the beginning of cooperation, every communication is the germ of innovation, and every product is a witness to industrial upgrading. I believe that with the holding of the exhibition, China's pharmaceutical industry will accelerate on the path of innovation driven development, participate in global competition with a more vigorous attitude, and write a new chapter of high-quality development.